GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, announced on October 27, 2026, that it has entered into an unsecured $1,000,000 Revolving Loan Agreement with Bowery Consulting Group Inc. The loan, dated October 23, 2026, carries a 12% annual interest rate and matures 12 months from issuance. Advances under the facility are subject to the lender's approval, giving Bowery significant control over the company's access to capital.
The agreement comes with substantial governance changes. On the same day, five directors—Randal Chase, Dean Kollintzas, Nicole Lemerond, Jayne Morgan, and John Spencer, Jr.—resigned, and Steven Brown, Tyler O’Brien, and Manpreet Uppal were appointed to the board. Each new director was nominated by the lender pursuant to the loan agreement. Following these changes, GeoVax’s board consists of five directors, and the company has determined that the new directors meet SEC and Nasdaq independence standards. Mr. O’Brien and Mr. Uppal will join the Audit Committee alongside Dr. Robert McNally.
David A. Dodd, Chairman and CEO of GeoVax, commented, “Securing this financing is an important achievement for GeoVax, reinforcing our balance sheet and providing the working capital needed to support our operations.” He welcomed the new directors, citing their diverse experience and leadership, and expressed appreciation to the departing members. Dodd also highlighted the company’s focus on advancing its GEO-MVA clinical program for mpox and smallpox, which is planned for a pivotal Phase 3 trial in late 2026.
The loan agreement’s requirement that the lender nominate three directors raises questions about control and strategic direction. While the financing strengthens GeoVax’s near-term liquidity, it also cedes considerable influence to Bowery Consulting Group. The lender’s approval is required for each advance, and the board overhaul may align the company’s priorities with the lender’s interests. This could affect GeoVax’s ability to pursue partnerships or financing on its own terms.
GeoVax’s pipeline includes GEO-MVA, an MVA-based vaccine for mpox and smallpox, and Gedeptin®, a gene-directed enzyme prodrug therapy for head and neck cancer. The company emphasizes its global intellectual property portfolio and ongoing evaluation of strategic partnerships. However, the new board composition and loan terms may shape these efforts.
Further details will be disclosed in a Form 8-K filed with the SEC. The announcement was initially reported by NEWMEDIAWIRE and can be viewed in full at www.newmediawire.com.
